Biotech · Public company · Durham, NC, US

Precision Biosciences Inc

Ticker DTIL · SEC CIK 0001357874

Track this companyFree. Adds Precision Biosciences Inc to your Dealase workspace and tells you when its record changes.

Clinical trials63 recruiting or active

Pipeline programs11From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline11

CyclophosphamidePhase 2 · Non-Hodgkin's Lymphoma, RelapsedClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Non-Hodgkin's Lymphoma, RelapsedClinicalTrials.gov · fetched Nov 12, 2026
PBCAR20APhase 2 · Non-Hodgkin's Lymphoma, RelapsedClinicalTrials.gov · fetched Nov 12, 2026
PBGENE-DMD (IV)Phase 2 · Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMDClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
NirogacestatPhase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
PBCAR19BPhase 1 · CD19 Expressing MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
PBCAR269APhase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
PBGENE-HBVPhase 1 · HEPATITIS B CHRONICClinicalTrials.gov · fetched Nov 12, 2026
PBGENE-HBVChronic HBV InfectionClinicalTrials.gov · fetched Nov 12, 2026

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)PHASE1_PHASE2 · RECRUITING · started Apr 24, 2026ClinicalTrials.gov NCT07429240 · fetched Nov 12, 2026
A Long-term Observational Study in Participants Who Have Received PBGENE-HBVENROLLING_BY_INVITATION · started Dec 25, 2025ClinicalTrials.gov NCT07254208 · fetched Nov 12, 2026
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis BPHASE1 · RECRUITING · started Nov 14, 2024ClinicalTrials.gov NCT06680232 · fetched Nov 12, 2026
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing MalignanciesPHASE1 · COMPLETED · started Jun 16, 2021ClinicalTrials.gov NCT04649112 · fetched Nov 12, 2026
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaPHASE1 · TERMINATED · started Apr 30, 2020ClinicalTrials.gov NCT04171843 · fetched Nov 12, 2026
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLPHASE1_PHASE2 · COMPLETED · started Mar 24, 2020ClinicalTrials.gov NCT04030195 · fetched Nov 12, 2026